Testicular feminisation syndrome

Reading File

Finding Sources

Searching PubMed

androgen insensitivity syndrome

Reading File

Loading Image

Here is a detailed, authoritative overview of Testicular Feminisation Syndrome (now more precisely called Complete Androgen Insensitivity Syndrome, CAIS):

Testicular Feminisation Syndrome (Complete Androgen Insensitivity Syndrome)

Terminology

The older eponym "testicular feminisation syndrome" has been replaced in modern clinical practice by Complete Androgen Insensitivity Syndrome (CAIS). It falls under the broader category of Disorders of Sex Development (DSD), specifically 46,XY DSD.

Genetics and Pathophysiology

Karyotype: 46,XY
Inheritance: X-linked recessive (the androgen receptor gene, AR, is on the X chromosome at Xq11-q12)
Incidence: ~1 in 10,000-20,000 live births
Molecular defect: Loss-of-function mutations in the AR gene - ranging from complete gene deletion to point mutations affecting the androgen-binding or DNA-binding domain of the androgen receptor protein

The core mechanism:

The androgen receptor (AR) normally forms a complex with testosterone and dihydrotestosterone (DHT). This complex then acts as a transcription factor to activate genes responsible for male phenotypic differentiation. In CAIS, the AR is absent or non-functional, so:

Testosterone cannot act on target tissues - the wolffian ducts do not develop into the male internal genitalia (epididymis, vas deferens, seminal vesicles)
The external genitalia do not masculinise - the genital tubercle, labioscrotal folds, and urethral folds all develop along the female "default" pathway
The testes still secrete Anti-Mullerian Hormone (AMH) normally - so Mullerian duct structures (uterus, fallopian tubes, upper vagina) are suppressed and absent

This explains the paradoxical result: no female internal organs AND no male internal/external organs - except for the short blind-ending vagina (derived from the urogenital sinus, which forms independently of androgens).

Clinical Features

17-year-old woman with CAIS (A) showing female phenotype with normal breast development; (B) testicular histology showing Sertoli-cell lined seminiferous tubules without germ cells

Fig. A: Classic female phenotype in CAIS. Fig. B: Testicular histology - seminiferous tubules lined by Sertoli cells, no germ cells, hypoplastic Leydig cells. (The Developing Human, 9th ed.)

Feature	Details
External genitalia	Unambiguously female - normal clitoris, labia majora (may be hypoplastic), labia minora
Vagina	Short, blind-ending pouch; no cervix
Uterus / tubes	Absent (suppressed by AMH in utero)
Gonads	Testes - located in abdomen, inguinal canal, or labia majora
Breast development	Normal (often above average) - from peripheral aromatisation of testosterone to oestradiol
Pubic/axillary hair	Sparse to absent (requires functional AR)
Menstruation	Primary amenorrhoea - the most common presenting complaint
Height	Often above average female height
Gender identity	Female - patients identify as female

Hormonal Profile

Hormone	Level	Reason
Testosterone	Mildly elevated (male range)	Normal testicular production, but not acting peripherally
LH	Elevated	Absent negative feedback from androgens on the hypothalamus/pituitary
FSH	Normal or slightly elevated
Oestradiol	Present	Peripheral aromatisation of testosterone by adipose tissue and Sertoli cells

The high LH drives the testes to produce increased testosterone, which aromatises to oestradiol - this is what drives breast development at puberty.

Presentations by Age

Neonate/infant: Inguinal hernia containing a testis in a phenotypic female (CAIS accounts for ~1% of all girls undergoing inguinal hernia repair - this is an important clinical clue)
Adolescent: Primary amenorrhoea with normal breast development but absent pubic/axillary hair
Adult: Infertility workup or incidental finding

Diagnosis

Chromosomal analysis: 46,XY karyotype in a phenotypic female
Pelvic ultrasound/MRI: Absent uterus and ovaries; testes may be visualised in the abdomen or inguinal canal
Hormonal studies: Elevated LH and testosterone; oestradiol present
Androgen-binding studies on genital skin fibroblasts: Absent or defective androgen receptor binding
Genetic testing: Mutation analysis of the AR gene confirms the diagnosis

Management

Gonadectomy (Gonadal Removal)

The retained testes carry a significant cancer risk:

~10% risk of malignant germ cell tumour (most commonly seminoma) after puberty, rising to ~33% by age 50 in some series
A 2026 systematic review on gonadal malignancy screening in AIS (PMID 41102125) and a 2026 systematic review on testicular cancer in intersex individuals (PMID 41508675) both confirm this elevated risk, reinforcing current guidelines
Current recommendation: Gonadectomy is advised, preferably after puberty (to allow spontaneous breast development from oestradiol), though some centres remove gonads at diagnosis with subsequent oestrogen replacement

Hormone Replacement Therapy

Following gonadectomy, oestrogen replacement therapy is required to maintain secondary sex characteristics, prevent osteoporosis, and provide cardiovascular protection

Vaginal Management

The vaginal pouch may be too short for comfortable sexual intercourse
First-line: Progressive self-dilation (Frank's technique)
Surgical options: Vaginoplasty (using skin grafts or bowel segment) if dilation fails

Psychological Support

Sensitive, ongoing counselling regarding diagnosis, fertility, and gender identity
Patients should be informed they cannot bear children (no uterus or ovaries)

Comparison: Complete vs. Partial AIS

Feature	Complete AIS (CAIS)	Partial AIS (PAIS)
External genitalia	Unambiguously female	Ambiguous (enlarged clitoris, partial fusion)
Pubic/axillary hair	Absent	May be present
Presentation	Primary amenorrhoea, inguinal hernia	Ambiguous genitalia at birth
AR defect	Complete loss of function	Partial - point mutations

Key Summary Points

CAIS is caused by X-linked loss-of-function mutations in the androgen receptor (AR) gene
46,XY karyotype with female phenotype, absent uterus/tubes, short blind vagina, absent pubic/axillary hair, normal breasts
Testes present (often inguinal) - AMH is secreted normally, suppressing Mullerian structures
Oestradiol from peripheral aromatisation of testosterone drives breast development
Primary amenorrhoea is the classic adolescent presentation
Gonadectomy recommended due to malignancy risk (~10%), followed by oestrogen HRT
Inheritance is X-linked recessive; the mother is a carrier

Sources: Smith and Tanagho's General Urology (19th ed.), The Developing Human Clinically Oriented Embryology, Costanzo Physiology (7th ed.), Thompson & Thompson Genetics and Genomics in Medicine (9th ed.), Harrison's Principles of Internal Medicine (22nd ed., 2025)

Recent evidence note: Two 2026 systematic reviews (PMIDs 41102125 and 41508675) both highlight the elevated gonadal malignancy risk in AIS, supporting current recommendations for gonadectomy and active surveillance protocols.

This is a shared conversation. Sign in to Orris to start your own chat.